Mustang Bio Inc (MBIO)vsBeiGene, Ltd. (ONC)
MBIO
Mustang Bio Inc
$0.51
-2.46%
HEALTHCARE · Cap: $4.07M
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates -12258026% more annual revenue ($6.13B vs $-50,000). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
MBIO
Avoid26
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBIO.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MBIO
The strongest argument for MBIO centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : MBIO
The primary concerns for MBIO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
MBIO profiles as a value stock while ONC is a growth play — different risk/reward profiles.
MBIO carries more volatility with a beta of 2.05 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 26/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mustang Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, is focused on translating medical advances in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester, Massachusetts.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?